Brief: Oncocyte Corp Says New CMS Reimbursement Price Rate Of $2,753 Per Result For Graftassurecore Assay
19/05/2025 21:52
May 19 (Reuters) - OncoCyte Corp OCX.O: ONCOCYTE CORP - NEW CMS REIMBURSEMENT PRICE RATE OF $2,753 PER RESULT FOR GRAFTASSURECORE ASSAY Source text: ID:nGNXXsJVL Further company coverage: OCX.O ((Reuters.Brief@thomsonreuters.com;))
Recent news on Insight Molecular Diagnostics
See all newsBrief: Insight Molecular Diagnostics Enters Amendment No. 2 To Merger Agreement On Sept 15, 2026
Insight Molecular Diagnostics Inc reports results for the quarter ended June 30 - Earnings Summary
Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a share - Earnings Preview
Insight Molecular Diagnostics Q1 loss narrows as costs drop
Brief: Insight Molecular Diagnostics Completes Key Milestones Advancing Graftassuredx Toward FDA Submission